Yan F, Wu S, Yuan W, Yang Q, Yang J, Cui D. Cell Biochemistry and Function. 2026. DOI: 10.1002/cbf.70246
Background & Rationale
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), involves chronic relapsing intestinal inflammation whose metabolic drivers remain incompletely understood. Altered lipid handling, including fatty acid oxidation (FAO), has been proposed to contribute to epithelial energy deficits and immune dysregulation in IBD, but the metabolic signatures distinguishing CD from UC, and the mechanistic role of FAO in disease pathogenesis, have not been fully characterised. The authors identify this as an important gap and designed a study combining metabolomic profiling with experimental work to determine how fatty acid metabolism differs between IBD subtypes and whether disrupted FAO contributes causally to intestinal inflammation.
Study Design
This was a metabolomics-based case-control study with experimental validation, not a randomised interventional trial. Untargeted metabolomic profiling was performed on samples from CD patients, UC patients, and non-IBD controls to identify differentially abundant metabolites and pathways, with particular focus on FAO. Pathway enrichment analysis determined which metabolic pathways differed significantly between groups. Metabolomic findings were then explored experimentally to assess the functional consequences of altered FAO-related metabolites or enzymes on intestinal epithelial or immune cell behaviour. The primary aim was to characterise disease-specific FAO alterations in CD and UC and provide experimental evidence for their mechanistic role, using standard multivariate and univariate metabolomics statistics.
Patient Population
The study included CD patients, UC patients, and non-IBD comparators, from whom samples were collected for metabolomic analysis. Detailed baseline demographics, disease activity indices, treatment exposure, and group sample sizes are not provided in the material available for this summary, nor are any group imbalances described. Readers requiring precise cohort characteristics should consult the full published article.
Key Findings
Metabolomic analysis revealed distinct metabolic profiles in CD and UC versus non-IBD controls, with FAO emerging as a pathway of interest showing altered activity in both IBD groups. FAO-associated metabolites differed between disease states, indicating disrupted fatty acid metabolism in both CD and UC, with some distinctions between the two conditions. Follow-up experimental work supported the metabolomic findings, showing that altered FAO-related metabolic activity influences intestinal epithelial or immune cell function relevant to gut inflammation. Exact fold-changes and quantitative comparisons between groups are not detailed in the available material; readers should consult the original publication for precise statistical values. No explicit null findings for the primary pathway analysis are indicated.
Discussion
The authors interpret their findings as evidence that disrupted FAO forms part of the broader metabolic disturbance in IBD, with implications for understanding how altered intestinal energy metabolism relates to chronic inflammation in CD and UC. The experimental component is described as providing mechanistic support for the metabolomic observations, linking FAO changes to functional effects relevant to inflammation. As this was a metabolomics and experimental study rather than an interventional trial, conventional adverse event and tolerability reporting does not apply and is not described. No safety outcomes or adverse events are reported, since the design did not involve therapeutic intervention in human participants.
Authors’ Conclusions
The authors conclude that FAO pathways are altered in both CD and UC, and that their combined metabolomic and experimental findings support a role for disrupted FAO in the metabolic and functional abnormalities seen in IBD. Specific limitations regarding sample size, generalisability, or mechanistic scope are not detailed in the available material; readers should consult the full publication for the authors’ complete conclusions and limitations.
Reference
Yan F, Wu S, Yuan W, Yang Q, Yang J, Cui D. Role of fatty acid oxidation in Crohn’s disease and ulcerative colitis: metabolomics analysis and experimental evidence. Cell Biochem Funct. 2026. doi:10.1002/cbf.70246.
This Scientific Publication Summary is an objective summary of the published trial for personal and educational use. It does not constitute clinical advice, endorsement of the intervention, or a recommendation to alter clinical practice.